Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice

European Neuropsychopharmacology

Volumn 24, Issue 11, 2014, Pages 1773-1783

  Kuteykin Teplyakov, Konstantin ^a   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

4 methylenedioxyamphetamine; 5 HT1A receptor; N Methyl 3; Oxytocin; Proteomics; Social behavior

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID B RECEPTOR; L 368899; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; PROTEOME; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; BORNANE DERIVATIVE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; NERVE PROTEIN; OXTR PROTEIN, MOUSE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; BIOINFORMATICS; BRAIN CORTEX; CONTROLLED STUDY; FEAR; HIPPOCAMPUS; ISOBARIC TAG FOR RELATIVE AND ABSOLUTE QUANTIFICATION TECHNOLOGY; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SOCIABILITY; SOCIAL BEHAVIOR; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BORNANES; BRAIN; LOCOMOTION; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; PIPERAZINES; PROTEOME; PYRIDINES; RECEPTORS, OXYTOCIN; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR;

EID: 84918580765     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.08.007     Document Type: Article

References (47)

1. Akimova E., Lanzenberger R., Kasper S. The serotonin-1A receptor in anxiety disorders. Biol. Psychiatry 2009, 66:627-635.
2. Amikishieva A.V., Semendyaeva S.N. Effects of baclofen on anxiety, sexual motivation, and olfactory perception in male mice in different psychoemotional states. Neurosci. Behav. Physiol. 2007, 37:929-937.
3. Bankson M.G., Yamamoto B.K. Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release. J. Neurochem. 2004, 91:852-859.
4. Baumgartner T., Heinrichs M., Vonlanthen A., Fischbacher U., Fehr E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 2008, 58:639-650.
5. Benturquia N., Courtin C., Noble F., Marie-Claire C. Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice. Brain Res. 2008, 1211:1-5.
6. Bexis S., Phillis B.D., Ong J., White J.M., Irvine R.J. Baclofen prevents MDMA-induced rise in core body temperature in rats. Drug Alcohol Depend. 2004, 74:89-96.
7. Blakemore S.J. The social brain in adolescence. Nat. Rev. Neurosci. 2008, 9:267-277.
8. Caldwell H.K. Neurobiology of sociability. Adv. Exp. Med. Biol. 2012, 739:187-205.
9. Careau V., Garland T. Performance, personality, and energetics: correlation, causation, and mechanism. Physiol. Biochem. Zool. 2012, 85:543-571.
10. Carson D.S., Guastella A.J., Taylor E.R., McGregor I.S. A brief history of oxytocin and its role in modulating psychostimulant effects. J. Psychopharmacol. 2013, 27:231-247.
11. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 2004, 26:137-144.
12. de Waal F.B. What is an animal emotion?. Ann. N Y Acad. Sci. 2011, 1224:191-206.
13. Decety J., Norman G.J., Berntson G.G., Cacioppo J.T. A neurobehavioral evolutionary perspective on the mechanisms underlying empathy. Prog. Neurobiol. 2012, 98:38-48.
14. Dumont G.J., Sweep F.C., van der Steen R., Hermsen R., Donders A.R., Touw D.J., van Gerven J.M., Buitelaar J.K., Verkes R.J. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc. Neurosci. 2009, 4:359-366.
15. Fantegrossi W.E., Murai N., Mathúna B.O., Pizarro N., de la Torre R. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J. Pharmacol. Exp. Ther. 2009, 329:1006-1015.
16. Federici M., Sebastianelli L., Natoli S., Bernardi G., Mercuri N.B. Electrophysiologic changes in ventral midbrain dopaminergic neurons resulting from (+/-) -3,4-methylenedioxymethamphetamine (MDMA-"Ecstasy"). Biol. Psychiatry 2007, 62:680-686.
17. Fernandez-Castillo N., Orejarena M.J., Ribases M., Blanco E., Casas M., Robledo P., Maldonado R., Cormand B. Active and passive MDMA ('ecstasy') intake induces differential transcriptional changes in the mouse brain. Genes Brain Behav. 2012, 11:38-51.
18. Fossati P. Neural correlates of emotion processing: from emotional to social brain. Eur. Neuropsychopharmacol. 2012, 22(Suppl 3):S487-491.
19. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., Lin J., Minguez P., Bork P., von Mering C., Jensen L.J. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41:D808-815.
20. Gandal M.J., Sisti J., Klook K., Ortinski P.I., Leitman V., Liang Y., Thieu T., Anderson R., Pierce R.C., Jonak G., Gur R.E., Carlson G., Siegel S.J. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl. Psychiatry 2012, 2:e142.
21. Gonzalez A., Nutt D.J. Gamma hydroxy butyrate abuse and dependency. J. Psychopharmacol. 2005, 19:195-204.
22. Gould G.G., Hensler J.G., Burke T.F., Benno R.H., Onaivi E.S., Daws L.C. Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior. J. Neurochem. 2011, 116:291-303.
23. Guastella A.J., MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm. Behav. 2012, 61:410-418.
24. Hasler F., Studerus E., Lindner K., Ludewig S., Vollenweider F.X. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J. Psychopharmacol. 2009, 23:923-935.
25. Hunt G.E., McGregor I.S., Cornish J.L., Callaghan P.D. MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res. Bull. 2011, 86:65-73.
26. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435:673-676.
27. Martinez-Turrillas R., Moyano S., Del Rio J., Frechilla D. Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on BDNF mRNA expression in rat frontal cortex and hippocampus. Neurosci. Lett. 2006, 402:126-130.
28. McLennan I.S., Taylor-Jeffs J. The use of sodium lamps to brightly illuminate mouse houses during their dark phases. Lab. Animals 2004, 38:384-392.
29. Mithoefer M.C., Wagner M.T., Mithoefer A.T., Jerome L., Martin S.F., Yazar-Klosinski B., Michel Y., Brewerton T.D., Doblin R. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J. Psychopharmacol. 2013, 27:28-39.
30. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3:287-302.
31. Moya P.R., Fox M.A., Jensen C.L., Laporte J.L., French H.T., Wendland J.R., Murphy D.L. Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacol. 2011, 11:3.
32. Nichols D.E., Hoffman A.J., Oberlender R.A., Jacob P., Shulgin A.T. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J. Med. Chem. 1986, 29:2009-2015.
33. Peça J., Ting J., Feng G. SnapShot: autism and the synapse. Cell 2011, 147(3):e701.
34. Ramos L., Hicks C., Kevin R., Caminer A., Narlawar R., Kassiou M., McGregor I.S. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology 2013, 38:2249-2259.
35. Ray T.S. Psychedelics and the human receptorome. PLoS One 2010, 5:e9019.
36. Rusyniak D.E., Zaretskaia M.V., Zaretsky D.V., DiMicco J.A. Microinjection of muscimol into the dorsomedial hypothalamus suppresses MDMA-evoked sympathetic and behavioral responses. Brain Res. 2008, 1226:116-123.
37. Sakai Y., Shaw C.A., Dawson B.C., Dugas D.V., Al-Mohtaseb Z., Hill D.E., Zoghbi H.Y. Protein interactome reveals converging molecular pathways among autism disorders. Sci. Transl. Med. 2011, 3:86ra49. (86ra49).
38. Schutt J., Falley K., Richter D., Kreienkamp H.J., Kindler S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J. Biol. Chem. 2009, 284:25479-25487.
39. Stove C.P., De Letter E.A., Piette M.H., Lambert W.E. Mice in ecstasy: advanced animal models in the study of MDMA. Curr. Pharm. Biotechnol. 2010, 11:421-433.
40. Thiriet N., Ladenheim B., McCoy M.T., Cadet J.L. Analysis of ecstasy (MDMA)-induced transcriptional responses in the rat cortex. Faseb J. 2002, 16:1887-1894.
41. Thompson M.R., Callaghan P.D., Hunt G.E., Cornish J.L., McGregor I.S. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience 2007, 146:509-514.
42. van Nieuwenhuijzen P.S., Kashem M.A., Matsumoto I., Hunt G.E., McGregor I.S. A long hangover from party drugs: residual proteomic changes in the hippocampus of rats 8 weeks after gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Neurochem. Int. 2010, 56:871-877.
43. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13:227-232.
44. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998, 19:241-251.
45. Williams P.D., Anderson P.S., Ball R.G., Bock M.G., Carroll L., Chiu S.H., Clineschmidt B.V., Culberson J.C., Erb J.M., Evans B.E. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl-4-(2-methylphenyl) piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. J. Med. Chem. 1994, 37:565-571.
46. Wisniewski J.R., Zougman A., Nagaraj N., Mann M. Universal sample preparation method for proteome analysis. Nat. Methods 2009, 6:359-362.
47. Xu L.M., Li J.R., Huang Y., Zhao M., Tang X., Wei L. AutismKB: an evidence-based knowledgebase of autism genetics. Nucl. Acids Res. 2012, 40:D1016-1022.